SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-050724
Filing Date
2024-02-28
Accepted
2024-02-28 16:18:59
Documents
16
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d791287d8k.htm   iXBRL 8-K 25041
2 EX-99.1 d791287dex991.htm EX-99.1 57313
6 GRAPHIC g791287g0228063838737.jpg GRAPHIC 2585
  Complete submission text file 0001193125-24-050724.txt   220548

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20240228.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20240228_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20240228_pre.xml EX-101.PRE 11267
17 EXTRACTED XBRL INSTANCE DOCUMENT d791287d8k_htm.xml XML 3640
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 24695682
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)